Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P655: A study to determine factors affecting clinical decision making in outpatients with inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Derwa Y.1, Gracie D.J.*1,2, Williams C.J.1, Sood R.1,2, Mumtaz S.1, Bholah M.H.1, Hamlin P.J.1, Ford A.C.1,2

1St. James's University Hospital, Leeds Gastroenterology Institute, Leeds, United Kingdom 2University of Leeds, LIBACS, Leeds, United Kingdom

P656: Is there a role for additional oral mesalamine therapy in the treatment of ulcerative proctitis with skip inflammation?ECCO '17 Barcelona
Year: 2017
Authors:

Choi Y.S.*1, Kim W.J.1, Kim J.K.1, Song K.-H.2, Jung H.-J.2

1Daehang Hospital, Gastroenterology, Seoul, South Korea 2Daehang Hospital, Surgery, Seoul, South Korea

P657: The predictors and clinical outcomes of follow up loss of clinics in patients with inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Kim K.O.1, Jang B.I.1, Koo E.J.*1, Kang M.K.1, Yang C.H.2

1Yeungnam University College of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Daegu, South Korea 2Dongguk University College of Medicine, Division of gastroenterology and Hepatology, department of Internal Medicine, Kyungju, Korea, Republic of

P658: The Inflammatory Bowel Disease Disability Index (IBD-DI) in ulcerative colitis is related to disease activity, need of immunosuppressive therapy and quality of lifeECCO '17 Barcelona
Year: 2017
Authors:

Morreale G.C., Calvaruso V., Sanfratello A., Cappello M.

Policlinico Paolo Giaccone, Gastroenterology Section, DiBiMis, University of Palermo, Italy, Palermo, Italy

P659: Therapeutic drug monitoring of anti-TNFα drugs in a UK tertiary IBD unitECCO '17 Barcelona
Year: 2017
Authors:

Barrow V.*1, Innes A.1, Thompson N.1, Mansfield J.1,2, Speight A.1,3

1Newcastle upon Tyne Hospitals Trust, Gastroenterology, Newcastle upon Tyne, United Kingdom 2Newcastle University, Institute of Genetic Medicine, Newcastle upon Tyne, United Kingdom 3Newcastle University, Institute of Cellular Medicine, Newcastle upon Tyne, United Kingdom

P660: Prevalence and clinical course of cytomegalovirus colitis in Asian patients with acute exacerbation of ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Lim W.-C., Lin H.

Tan Tock Seng Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore

P661: Comparable clinical efficacy, safety and immunogenicity of infliximab biosimilar (CT-P13) after transition from reference infliximab (Remicade®) in children with established inflammatory bowel disease: a multi-centre prospective observational studyECCO '17 Barcelona
Year: 2017
Authors:

Sladek M.*1, Vultaggio A.2, Ghione S.3, Nencini F.2, Matucci A.2, Pratesi S.2, Zanieri F.4, Maggi P.M.2, Paci M.5, Ponanta-Gawron K.1, Kulig K.6, Wasilewska A.1, Lionetti P.7

1Jagiellonian University Medical College, Department of Pediatrics, Gastroenterology and Nutrition, Krakόw, Poland 2University of Florence, Centre of Research DENOTHE and Department of Experimental and Clinical Medicine, Florence, Italy 3Univeristy of Florence, Florence, Italy 4University of Florence, Florence, Italy 5Meyer Children's Hospital, Florence, Italy 6Univeristy Hospital in Krakow, Krakow, Poland 7University of Florence, Department of Neuroscience, Psychology, Drug Research and Child Health, Meyer Children's Hospital, Florence, Italy

P662: Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysisECCO '17 Barcelona
Year: 2017
Authors:

Paschos P.1,2, Katsoula A.2, Giouleme O.*2, Tsapas A.1,3

1Aristotle University, Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Thessaloniki, Greece 2Aristotle University, Second Propedeutic Medical Department, Thessaloniki, Greece 3University of Oxford, Harris Manchester College, Oxford, United Kingdom

P663: Switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: one year follow-up of a prospective observational cohort studyECCO '17 Barcelona
Year: 2017
Authors:

Smits L.*1, Grelack A.1, Drenth J.1, de Jong D.1, Boshuizen R.2, van Esch A.1, Derikx L.1, Hoentjen F.1

1Radboud university medical centre, Gastroenterology and Hepatology, Nijmegen, Netherlands 2Sanquin Diagnostic Services, Biologics Laboratory, Amsterdam, Netherlands

P664: The transitioning healthcare economy of IBD: changes in resource allocation over timeECCO '17 Barcelona
Year: 2017
Authors:

Spizzo P.

St Vincent's Hospital Melbourne, Victoria, Australia

P665: Unchanged infliximab serum concentrations after switching from the reference infliximab to the biosimilar CT-P13 in patients with quiescent Crohn's disease: a prospective studyECCO '17 Barcelona
Year: 2017
Authors:

Strik A.*1, van de Vrie W.2, van Megen Y.3, Bloemsaat-Minekus J.3, Rispens T.4, D'Haens G.1

1Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, Netherlands 2Albert Schweitzer Hospital, Department of Gastroenterology and Hepatology, Dordrecht, Netherlands 3Mundipharma Pharmaceuticals BV, Hoevelaken, Netherlands 4Academic Medical Center (AMC), Tytgat Institute for Intestinal and Liver Research, Amsterdam, Netherlands

P666: Short-term outcomes of adalimumab for patients with Crohn's disease and associated prognostic factors: a multicentre retrospective cohort studyECCO '17 Barcelona
Year: 2017
Authors:

Nasuno M.*1, Tanaka H.1, Miyakawa M.1, Motoya S.1, Ishii M.2, Shiotani A.2, Yamashita M.3, Itoh F.3, Tanuma T.4, Sakemi R.5, So S.5, Suzuki R.6, Yanagisawa H.7, Onodera K.8, Kaneto H.9, Nojima M.10, Nakase H.8

1Sapporo Kosei General Hospital, IBD Center, Sapporo, Japan 2Kawasaki Medical School, Department of Internal Medicine, Division of Gastroenterology, Kurashiki, Japan 3St. Marianna University School of Medicine, Division of Gastroenterology and Hepatology, Kawasaki, Japan 4Teine Keijinkai Hospital, Center for Gastroenterology, Sapporo, Japan 5Tobata Kyoritsu Hospital, Department of Gastroenterology, Kitakyusyu, Japan 6Hakodate Goryoukaku Hospital, Department of Gastroenterology, Hakodate, Japan 7Obihiro Kosei General Hospital, Department of Gastroenterology and Hepatology, Obihiro, Japan 8Sapporo Medical University, School of Medicine, Department of Gastroenterology and Hepatology, Sapporo, Japan 9Muroran City General Hospital, Department of Gastroenterology, Muroran, Japan 10The University of Tokyo, The Institute of Medical Science, Center for Translational Research, Tokyo, Japan

P667: Safety of anti-TNF treatment in liver transplant recipients – a meta-analysisECCO '17 Barcelona
Year: 2017
Authors:

Westerouen van Meeteren M.1, Inderson A.1, Hayee B.2, van der Meulen A.1, Altwegg R.3, van Hoek B.1, Pageaux G.-P.3, Stijnen T.4, Stein D.5, Maljaars J.*1

1LUMC, Department of Gastroenterology-Hepatology, Leiden, Netherlands 2King's College Hospital, Department of Gastroenterology, London, United Kingdom 3University Hospital of St. Eloi, Department of Hepatology and Gastroenterology, Montpellier, France 4LUMC, Department of Medical statistics, Leiden, Netherlands 5Medical College of Wisconsin, Division of Gastroenterology and Hepatology, Milwaukee, United States

P668: Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infectionsECCO '17 Barcelona
Year: 2017
Authors:

Bhayat F.1, Blake A.*2, Travis S.3

1Takeda Development Centre Europe Ltd, Global Pharmacovigilance, London, United Kingdom 2Takeda Development Center Europe Ltd, Global Pharmacovigilance, London, United Kingdom 3University of Oxford, Translational Gastroenterology Unit, Nuffield Department of Medicine, Oxford, United Kingdom

P669: Adalimumab long-term effectiveness in adalimumab-naïve patients with Crohn's disease: final data from PYRAMID registryECCO '17 Barcelona
Year: 2017
Authors:

Loftus Jr. E.*1, D'Haens G.2, Reinisch W.3, Satsangi J.4, Panaccione R.5, Berg S.6, Alperovich G.7, Bereswill M.8, Kalabic J.8, Skup M.9, Petersson J.9, Robinson A.M.9

1Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States 2Academic Medical Centre, Department of Gastroenterology, Amsterdam, Netherlands 3Medical University of Vienna, Vienna, Austria 4Western General Hospital, Gastrointestinal Unit, Edinburgh, United Kingdom 5University of Calgary, Department of Medicine, Calgary, Canada 6AbbVie AB, Solna, Sweden 7AbbVie Spain S.L.U., Madrid, Spain 8AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany 9AbbVie Inc., North Chicago, United States

P670: Evaluating the management of Vitamin D in Crohn's disease patients in a secondary care populationECCO '17 Barcelona
Year: 2017
Authors:

Ahmed R., O'Connell G., Love M., Davis J., Cooney R., Pathmakanthan S., Iqbal T., Bhala N.

Queen Elizabeth Hospital Birmingham, University Hospitals Birmigham NHS Foundation Trust, Gastroenterology, Birmingham, United Kingdom

P671: Early suppression of the serological macrophage activity biomarker VICM, and not suppression of CRP, predicts the response to infliximab in Crohn's disease patientsECCO '17 Barcelona
Year: 2017
Authors:

Mortensen J.H.*1, van Haaften W.T.2,3, Olesen M.L.1,4, Karsdal M.1, Olinga P.2, Dijkstra G.3, Bay-Jensen A.-C.1

1Nordic Bioscience, Biomarkers & Research, Herlev, Denmark 2University Medical Center Groningen, Department of Pharmaceutical Technology and Biopharmacy, Groningen, Netherlands 3University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands 4University of Southern Denmark and Odense University Hospital, Department of Medical Gastroenterology, Odense, Denmark

P672: Surgical and anti-TNFs combined therapy prevents Crohn's perianal fistula recurrence: a systematic review and meta-analysisECCO '17 Barcelona
Year: 2017
Authors:

Xu P.-p.*1, Qiu Y.2, Jia Y.-l.1, Xu L.1, He C.-y.1, Han Z.1

1The First Affiliated Hospital of Wannan Medical College, Wuhu, China 2The First Affiliated Hospital of Sun Yat-Sen Medical University, Guangzhou, China

P673: Intra-abdominal collections in Crohn's disease: outcomes following anti-TNF therapyECCO '17 Barcelona
Year: 2017
Authors:

Subramaniam K.*1,2, Tweedale M.1, Pavli P.1,2

1Canberra Hospital, Gastroenterology and Hepatology Unit, Canberra, Australia 2Australian National University, ANU Medical School, Canberra, Australia

P674: Potential utility of therapeutic drug monitoring of adalimumab in predicting short-term mucosal healing and histologic remission in paediatric Crohn's disease patientsECCO '17 Barcelona
Year: 2017
Authors:

Kang B.*1, Lee K.1, Choe B.-H.2, Choe Y.H.1

1Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Pediatrics, Seoul, South Korea 2Kyungpook National University Hospital, Kyungpook National University School of Medicine, Department of Pediatrics, Daegu, South Korea